Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shirit Einav

Showing results (11-20 of 78) with videos related to

Pageof 8
Sort By:
Journal of Virology|September 29, 2004
A nucleotide binding motif in hepatitis C virus (HCV) NS4B mediates HCV RNA replicationShirit Einav, Menashe Elazar, Tsafi Danieli, et al.
Cellular and Molecular Life Sciences : CMLS|July 26, 2018
Viral journeys on the intracellular highwaysMakeda Robinson, Stanford Schor, Rina Barouch-Bentov, et al.
Nature Reviews. Drug Discovery|September 10, 2021
PIKfyve: a lipid kinase target for COVID-19, cancer and neurodegenerative disordersPei-Tzu Huang, Shirit Einav, Christopher R M Asquith
The Journal of Infectious Diseases|May 22, 2010
The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitorsShirit Einav, Hadas D Sobol, Elizabeth Gehrig, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 22, 2002
Complement C4 is protective for lupus disease independent of C3Shirit Einav, Olga O Pozdnyakova, Minghe Ma, et al.
Nature Reviews. Drug Discovery|February 18, 2026
PIP4K2C: an emerging fulcrum for multiple diseasesLuca Pozzetti, Manjari Mishra, Shirit Einav, et al.
Bioorganic & Medicinal Chemistry Letters|October 8, 2021
Identification and evaluation of 4-anilinoquin(az)olines as potent inhibitors of both dengue virus (DENV) and Venezuelan equine encephalitis virus (VEEV)Sirle Saul, Pei-Tzu Huang, Shirit Einav, et al.
Molecules (Basel, Switzerland)|December 10, 2021
Optimization of 4-Anilinoquinolines as Dengue Virus InhibitorsPei-Tzu Huang, Sirle Saul, Shirit Einav, et al.
Elife|February 17, 2018
Single-cell transcriptional dynamics of flavivirus infectionFabio Zanini, Szu-Yuan Pu, Elena Bekerman, et al.
STAR Protocols|February 24, 2024
Chemical inactivation strategies for SARS-CoV-2-infected cells and organoidsMarwah Karim, Amol Arunrao Pohane, Chieh-Wen Lo, et al.
Pageof 8

Showing results (11-20 of 78) with videos related to

Sort By:
Pageof 8
Journal of Virology|September 29, 2004
A nucleotide binding motif in hepatitis C virus (HCV) NS4B mediates HCV RNA replicationShirit Einav, Menashe Elazar, Tsafi Danieli, et al.
Cellular and Molecular Life Sciences : CMLS|July 26, 2018
Viral journeys on the intracellular highwaysMakeda Robinson, Stanford Schor, Rina Barouch-Bentov, et al.
Nature Reviews. Drug Discovery|September 10, 2021
PIKfyve: a lipid kinase target for COVID-19, cancer and neurodegenerative disordersPei-Tzu Huang, Shirit Einav, Christopher R M Asquith
The Journal of Infectious Diseases|May 22, 2010
The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitorsShirit Einav, Hadas D Sobol, Elizabeth Gehrig, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 22, 2002
Complement C4 is protective for lupus disease independent of C3Shirit Einav, Olga O Pozdnyakova, Minghe Ma, et al.
Nature Reviews. Drug Discovery|February 18, 2026
PIP4K2C: an emerging fulcrum for multiple diseasesLuca Pozzetti, Manjari Mishra, Shirit Einav, et al.
Bioorganic & Medicinal Chemistry Letters|October 8, 2021
Identification and evaluation of 4-anilinoquin(az)olines as potent inhibitors of both dengue virus (DENV) and Venezuelan equine encephalitis virus (VEEV)Sirle Saul, Pei-Tzu Huang, Shirit Einav, et al.
Molecules (Basel, Switzerland)|December 10, 2021
Optimization of 4-Anilinoquinolines as Dengue Virus InhibitorsPei-Tzu Huang, Sirle Saul, Shirit Einav, et al.
Elife|February 17, 2018
Single-cell transcriptional dynamics of flavivirus infectionFabio Zanini, Szu-Yuan Pu, Elena Bekerman, et al.
STAR Protocols|February 24, 2024
Chemical inactivation strategies for SARS-CoV-2-infected cells and organoidsMarwah Karim, Amol Arunrao Pohane, Chieh-Wen Lo, et al.
Pageof 8